The $600m venture financing of CMR Surgical was the medical devices industry’s top cross border venture financing deal as total deals worth $2bn were announced globally in June 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 18.2% over the previous month of $1.7bn and a rise of 260.6% when compared with the last 12-month average, which stood at $557.38m.
Comparing cross border venture financing deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $945.5m. At the country level, the US topped the list in terms of deal value at $896.7m.
In terms of volumes, North America emerged as the top region for medical devices industry cross border venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of cross border venture financing deals activity in June 2021 was the US with 14 deals, followed by the UK with three and China with three.
In 2021, as of June, medical devices cross border venture financing deals worth $5.88bn were announced globally, marking an increase of 145.7% year on year.
medical devices industry cross border venture financing deals in June 2021: Top deals
The top five medical devices industry cross border venture financing deals accounted for 76.2% of the overall value during June 2021.
The combined value of the top five medical devices cross border venture financing deals stood at $1.53bn, against the overall value of $2bn recorded for the month.
The top five medical devices industry cross border venture financing deals of June 2021 tracked by GlobalData were:
1) Ally Bridge Group, Cambridge Innovation Capital, Chimera Partners, GE Healthcare, LGT Impact Ventures, Lightrock, PFM Health Sciences, RPMI Railpen, SoftBank Vision Fund II, Tencent Holdings and Watrium’s $600m venture financing of CMR Surgical
2) The $276m venture financing of Element Biosciences by Counterpoint Global, Janus Henderson Investors, Logos Global Management, Meritech Capital Partners and T Rowe Price Associates
3) B Capital Group Management, Baidu Ventures, Bold Capital Partners, CITIC Industrial Investment Fund Management, Deerfield ManagementLP, Eight Roads Ventures, Formic Ventures, Lake Bleu Capital, Lilly Asia ventures, Maison Capital Group, Mirae Asset Capital, Orbimed Advisors, Pavilion Capital Partners, President International Development, Qiming Venture Partners, Sage Partners, Sequoia Capital China, Sinovation Ventures and Warburg Pincus’ $255m venture financing of InSilico Medicine
4) The $245m venture financing of Quanta Dialysis Technologies by BlackRock, btov Partners, Eldridge Industries, Glenview Capital Management, Millennium Management, Monashee Investment Management, Novo Holdings, Orlando Health, Puhua Capital, Sands Capital Management, Segulah, Seroba Life Sciences Management and Wellington Partners
5) Chaosheng Capital, Heyu Capital and Volcanic Stone Capital’s venture financing of Shanghai Diying Biotechnoogy for $156.27m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.